Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus PT from Analysts

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have received an average rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $23.67.

ACRV has been the subject of several recent analyst reports. BMO Capital Markets cut their price objective on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. JMP Securities reiterated a “market outperform” rating and issued a $17.00 price target on shares of Acrivon Therapeutics in a research note on Monday, September 16th. LADENBURG THALM/SH SH raised shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Acrivon Therapeutics in a report on Thursday, November 14th. Finally, Piper Sandler Companies reissued a “buy” rating and set a $30.00 price target on shares of Acrivon Therapeutics in a research report on Friday, September 6th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC grew its position in shares of Acrivon Therapeutics by 78.2% in the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock valued at $31,093,000 after purchasing an additional 2,353,000 shares during the last quarter. Sands Capital Ventures LLC increased its position in Acrivon Therapeutics by 28.4% during the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock worth $12,311,000 after buying an additional 470,000 shares during the period. Marshall Wace LLP lifted its holdings in shares of Acrivon Therapeutics by 58.8% during the second quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock worth $5,503,000 after buying an additional 351,397 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Acrivon Therapeutics in the second quarter valued at about $61,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Acrivon Therapeutics in the second quarter valued at about $58,000. 71.62% of the stock is owned by institutional investors.

Acrivon Therapeutics Stock Performance

ACRV opened at $5.41 on Thursday. The business’s 50-day simple moving average is $7.31 and its 200 day simple moving average is $7.50. Acrivon Therapeutics has a 52-week low of $3.19 and a 52-week high of $11.90. The firm has a market capitalization of $168.45 million, a PE ratio of -2.00 and a beta of 0.55.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.